Dupixent CTCL Lawsuits: The Next Emerging MDL
https://llamalab-website-1ef24.web.app/blog/dupixent-ct…
Case summary
The target, observed result, and important findings.
- Status
- Current evaluation
Limited evidence: critical response missing, interaction stalled
- Findings
- 5Low
- Submitted URL
- https://llamalab-website-1ef24.web.app/blog/category/mass-tort-news Search for this value.
- Domain registration
- web.appMore than 90 days oldRegistered 2019-01-08 · Registrar MarkMonitor Inc.
- Language
- Detecting...
- Network
- 146 requests across 36 hosts
- Cookies
- 60 observed
- Infrastructure
- Loading...
- Behavior
- 2 recorded events
- Interaction
3 actions · 0 submissions · stopped: repeated state · download stage: no payload control
- 1. clicksucceededMass Tort News 6 min read Dupixent CTCL Lawsuits: The Next Emerging MDL Plaintiffs are moving to centralize Dupixent cutaneous T-cell lymphoma cases as an MDL after the FDA flagged a safety signal. ma
- 2. clicksucceededNext Steps for Law Firms
- 3. clicksucceededNext Steps for Law Firms